PA-BOOMI
31.1.2024 15:01:34 CET | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, is proud to announce that it has been granted two new patents by the United States Patent and Trademark Office (USPTO) in the field of Artificial Intelligence (AI). These patents boost Boomi's total patent number to 36, underscoring the company's commitment to innovation and its ongoing efforts to push the boundaries of AI advancement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131961796/en/
Boomi Secures Two Patents for AI Innovation (Graphic: Business Wire)
The newly granted U.S. Patent No. 11,886,965, titled “Artificial-Intelligence-Assisted Construction of Integration Processes,” encompasses the underlying technology of features that allow Boomi’s customers to build integrations based on Boomi suggestions, including Shape Suggest, Quick Start, and more recently, Boomi AI. This innovation addresses the steep learning curve that users, both novice and expert, face when constructing integration processes on an integration platform.
Employing machine learning models – based on a Markov chain or various forms of graph neural networks – facilitates a predictive guidance system for users, enhancing the efficiency and effectiveness of constructing integration processes.
“Our patent award for ‘Artificial-Intelligence-Assisted Construction of Integration Processes’ stands as a notable innovation in the domain of integration platform as a service (iPaaS), and is a testament to the hard work and dedication of our talented team of engineers, scientists, and innovators,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “The contributions through this patent fundamentally challenge the existing paradigms inherent when constructing integration processes. Before this innovation, the construction of integration processes largely relied on the user's expertise and manual inputs using a drag and drop UI, which could be time-consuming and prone to errors, especially for those new to the platform. This AI-driven approach has transitioned construction of integration processes to an intelligent, predictive, and guided task.”
Boomi was also recently granted U.S. Patent No. 11,847,167, titled “System and Method for Generation of Chat Bot System with Integration Elements Augmenting Natural Language Processing and Native Business Rules.” This patent is for a technology solution built on the Boomi platform that creates a series of templatized processes and designs. This allows Boomi customers to build hybrid chatbots that combine rules-based connectivity, natural language processing, Boomi logic, and AI technologies to triage and route requests coming into the chatbot. This technology helped lay the foundation for Retrieval Augmented Generation and demonstrates Boomi’s early innovations in applying AI to integration.
Macosky added, “Achieving these patents reaffirms our commitment to continuous innovation and underscores our position as a leader in the industry. We are excited about the potential impact our AI patents will have for our customers and partners, and we look forward to continuing our mission of driving transformation through intelligent integration and automation.”
Additional Resources
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131961796/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom